Tranexamic Acid for Gastritis
Tranexamic acid is NOT indicated for gastritis. The FDA-approved indication for tranexamic acid is limited to patients with hemophilia undergoing tooth extraction, not for gastritis or general gastrointestinal bleeding 1.
Critical Distinction: Gastritis vs. Gastrointestinal Bleeding
Gastritis refers to inflammation of the gastric mucosa and is fundamentally different from acute gastrointestinal hemorrhage 1.
Tranexamic acid is an antifibrinolytic agent designed to prevent clot breakdown in active bleeding scenarios, not to treat mucosal inflammation 1.
Evidence for Gastrointestinal Bleeding (Not Gastritis)
While your question asks about gastritis specifically, it's important to understand the evidence for tranexamic acid in GI bleeding, as this may be the intended clinical scenario:
Guideline Recommendations
Current guidelines do NOT recommend routine tranexamic acid use for non-variceal upper gastrointestinal hemorrhage 2.
A meta-analysis showed tranexamic acid may reduce need for surgical intervention and tend to reduce mortality, but the evidence was considered insufficient due to methodological concerns, including disproportionate influence from a single large trial with unusually high mortality in the control group 2.
Guidelines explicitly state "further studies of tranexamic acid are necessary before it can be recommended as routine therapy" 2.
Recent High-Quality Evidence
The landmark HALT-IT trial (2020) definitively showed tranexamic acid does NOT reduce mortality in gastrointestinal bleeding:
Death from bleeding occurred in 4% of both tranexamic acid and placebo groups (RR 0.99,95% CI 0.82-1.18) 3.
Tranexamic acid INCREASED venous thromboembolic events (0.8% vs 0.4%; RR 1.85,95% CI 1.15-2.98) 3.
Based on these results, the authors concluded tranexamic acid should NOT be used for gastrointestinal bleeding outside of clinical trials 3.
Conflicting Meta-Analyses
A 2025 meta-analysis suggested benefit for upper GI bleeding but showed INCREASED mortality in lower GI bleeding (RR 1.67,95% CI 1.44-1.93) 4.
A 2022 systematic review found high-dose IV tranexamic acid increased deep vein thrombosis (RR 2.01), pulmonary embolism (RR 1.78), and seizures (RR 1.73) without reducing mortality or bleeding 5.
Clinical Bottom Line
Do not use tranexamic acid for gastritis. If the clinical scenario involves acute upper gastrointestinal bleeding from peptic ulcer disease:
Prioritize high-dose proton pump inhibitor therapy (omeprazole 80 mg IV bolus followed by 8 mg/hour infusion for 72 hours) following endoscopic hemostasis 2.
Avoid tranexamic acid given the lack of mortality benefit and increased thromboembolic risk demonstrated in the highest quality evidence 3.
Focus on endoscopic therapy and acid suppression as the evidence-based standard of care 2.